Lack of ldl receptor enhances amyloid deposition and decreases glial response in an alzheimer's disease mouse model

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Katsouri, Loukia ^a   Georgopoulos, Spiros ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; AMYLOID BETA PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; THIAZOLE DERIVATIVE; THIOFLAVINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN REGION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE DELETION; GLIA CELL; HIPPOCAMPUS; MICROGLIOSIS; MOUSE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN METABOLISM; SUBICULUM; ANIMAL; DISEASE MODEL; GLIA; HUMAN; METABOLISM; MICROGLIA; PATHOLOGY; PROTEIN PROCESSING; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; ASTROCYTES; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; NEUROGLIA; PLAQUE, AMYLOID; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, LDL; THIAZOLES;

EID: 79959926626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021880     Document Type: Article

References (40)

1. Selkoe DJ, (1991) The molecular pathology of Alzheimer's disease. Neuron 6: 487-498.
2. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, et al. (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68: 613-618.
3. Kim J, Basak JM, Holtzman DM, (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63: 287-303.
4. Mahley RW, (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.
5. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, et al. (1999) Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J Clin Invest 103: R15-R21.
6. Buttini M, Yu GQ, Shockley K, Huang Y, Jones B, et al. (2002) Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J Neurosci 22: 10539-10548.
7. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 96: 15233-15238.
8. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, et al. (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17: 263-264.
9. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, et al. (2000) Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47: 739-747.
10. Herz J, Beffert U, (2000) Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat Rev Neurosci 1: 51-58.
11. Herz J, (1993) The LDL-receptor-related protein- portrait of a multifunctional receptor. Current Opinion in Lipidology 4: 107-113.
12. Hobbs HH, Russell DW, Brown MS, Goldstein JL, (1990) The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24: 133-170.
13. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883-893.
14. Leduc V, Jasmin-Belanger S, Poirier J, (2010) APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 16: 469-477.
15. Linton MF, Babaev VR, Gleaves LA, Fazio S, (1999) A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation. Journal of Biological Chemistry 274: 19204-19210.
16. Mahley RW, Ji ZS, (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40: 1-16.
17. Bu G, (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Rofo 10: 333-344.
18. Lamsa R, Helisalmi S, Herukka SK, Tapiola T, Pirttila T, et al. (2008) Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. Neurobiol Aging 29: 848-855.
19. Zou F, Gopalraj RK, Lok J, Zhu H, Ling IF, et al. (2008) Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. Hum Mol Genet 17: 929-935.
20. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, et al. (2005) The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem 280: 25754-25759.
21. Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S, (2010) Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc Natl Acad Sci U S A 107: 20816-20821.
22. Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, et al. (2005) The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem 280: 43243-43256.
23. Wahrle SE, Hong J, Parsadanian M, Hartman RE, Bales KR, et al. (2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280: 43236-43242.
24. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, et al. (2004) ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 165: 1413-1422.
25. Cao D, Fukuchi K, Wan H, Kim H, Li L, (2006) Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging 27: 1632-1643.
26. Abazov VM, Abbott B, Abolins M, Acharya BS, Adams M, et al. (2009) Search for large extra spatial dimensions in the dielectron and diphoton channels in pp[over] collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett 102: 051601.
27. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, et al. (2009) Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64: 632-644.
28. Oakley H, Cole SL, Logan S, Maus E, Shao P, et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26: 10129-10140.
29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
30. Benjamin R, Leake A, McArthur FK, Ince PG, Candy JM, et al. (1994) Protective effect of apoE epsilon 2 in Alzheimer's disease. Lancet 344: 473.
31. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, et al. (2001) Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 158: 1173-1177.
32. Wang J, Tanila H, Puolivali J, Kadish I, van Groen T, (2003) Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis 14: 318-327.
33. Vina J, Lloret A, (2011) Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis 20 (Suppl 2): S527-533.
34. Kashon ML, Ross GW, O'Callaghan JP, Miller DB, Petrovitch H, et al. (2004) Associations of cortical astrogliosis with cognitive performance and dementia status. J Alzheimers Dis 6: 595-604; discussion 673-581.
35. Nagele RG, Wegiel J, Venkataraman V, Imaki H, Wang KC, (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25: 663-674.
36. Zlokovic BV, (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89: 807-811.
37. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, et al. (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27: 909-918.
38. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106: 1489-1499.
39. Yancey PG, Jerome WG, Yu H, Griffin EE, Cox BE, et al. (2007) Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI. J Lipid Res 48: 1140-1149.
40. Anderson JP, Refolo LM, Wallace W, Mehta P, Krishnamurthi M, et al. (1989) Differential brain expression of the Alzheimer's amyloid precursor protein. Embo J 8: 3627-3632.